comparemela.com

Latest Breaking News On - Plasma cell myeloma - Page 3 : comparemela.com

In Real World, Patients With Myeloma Have Worse Outcomes

A new analysis found that patients with multiple myeloma receiving standard therapies have much worse outcomes compared with those treated in clinical trials.

United statesUniversity of miamiAlissa visramMikkaela sekeresCynthiae dunbarBlood instituteNational heartOttawa hospital research instituteAmerican society of hematologyTranslational stem cell biology branchDivision of hematologySylvester comprehensive cancer centerAmerican societyMultiple myelomaPlasma cell myelomaClinical research

Time to Stop Routine Maintenance Therapy in Myeloma?

Physicians may need to rethink maintenance with lenalidomide (Revlimid and generics) for multiple myeloma.

United statesNew yorkMemorial sloan kettering cancer centerNikhil munshiSergio giraltBenjamin dermanShaji kumarInternational myeloma working groupUniversity of alabama at birminghamUniversity of chicagoNational comprehensive cancer network multiple myeloma guidelinesHarvard medical schoolLancet haematologyLuciano costaNew england journalMayo clinic

Survival on the Upswing in Multiple Myeloma

Hematologists are heralding a new era in multiple myeloma. Experts discuss how times have changed.

United statesTom brokawStanley katzRafael fonsecaJamesr berensonSteve scaliseLos angelesNational cancer instituteWinship cancer instituteAmerican society of hematologyEmory universityNational comprehensive cancer networkCaris life sciencesWest hollywoodSagar lonialWinship cancer

Debate: Should Smoldering Myeloma Be Treated?

The two experts based their arguments largely on the same two studies, the only randomized trials to tackle the issue to date.

United statesAngela dispenzieriEmory universitySociety of hematologic oncologyHematologic oncologySagar lonialMayo clinicMultiple myelomaPlasma cell myelomaBiologic therapyMalignant melanomaSkin cancerAlignant skin neoplasm

FDA OKs Motixafortide for Stem Cell Mobilization in Myeloma

The GENESIS trial reported substantially better stem cell mobilization when patients with multiple myeloma received motixafortide alongside filgrastim.

Philip serlinDrug administrationMultiple myelomaPlasma cell myelomaTransplantation stem cellRansplantation hematopoietic stem cellHematopoietic stem cell transplantationStem cell transplantationStem cell therapyHerapy stem cellTransplantation cellularCellular transplantationUs food and drug administrationNited states food and drug administration

vimarsana © 2020. All Rights Reserved.